Adds illicit fentanyls to Schedule I in the "New Jersey Controlled Dangerous Substances Act."
The immediate impact of A998 would codify the existing administrative decision that placed certain illicit fentanyls under Schedule I, enhancing the legal framework to control and penalize the manufacture, distribution, and dispensing of these substances. By doing so, the bill aims to provide law enforcement with stronger tools to tackle the growing problem of fentanyl-related overdoses and fatalities in New Jersey. Existing penalties for Schedule I violations would apply, including significant fines and prison time for trafficking in these substances, which could serve as a deterrent.
Bill A998 proposes to add illicit fentanyls to Schedule I of the New Jersey Controlled Dangerous Substances Act. The designation of Schedule I indicates that these substances have a high potential for abuse, no accepted medical use in treatment within the United States, or lack accepted safety for use under medical supervision. This includes several specific compounds that are not FDA-approved drugs and are derivatives of the controlled substance fentanyl, which has been an increasing concern due to its role in the opioid epidemic affecting the state and the country at large.
As is common with drug legislation, A998 may face contention regarding its broader implications on public health and treatment. Critics may argue that while regulating illicit fentanyls is crucial for addressing the opioid crisis, it should be paired with comprehensive addiction treatment and prevention strategies. There may be concerns regarding access to needed medications for pain and the unintended consequences of strict laws that could affect patients who legitimately need opioid medications for legitimate medical purposes.